Skip to Content

Is Spravato (esketamine) a controlled substance?

Medically reviewed by Last updated on Sep 10, 2019.

Official Answer


Yes. Spravato (esketamine) is a Schedule III Controlled Substance in the United States.

Spravato is rapid acting nasal spray used conjunction with an oral antidepressant, for use in adults with treatment-resistant depression. It was approved by the FDA in March 2019.

Spravato contains esketamine, which is the s-enantiomer of ketamine. Ketamine is a mixture of two enantiomers (mirror image molecules). The FDA first approved ketamine (Ketalar) in 1970 for use as a rapid-acting general anesthetic, but in more recent times has become known as a drug of abuse (Special K) due to its hallucinogenic properties.

Both esketamine and ketamine are listed under schedule III of the Controlled Substances Act (CSA).


Related Medical Questions

Drug Information

Related Support Groups